Target intelligence / Profile preview

G protein-coupled receptor 22 (GPR22)

Target
GPR22
Molecular classification
G protein-coupled receptor, Rhodopsin-like receptor, Seven transmembrane domain receptor
01

Overview

G protein-coupled receptor 22 (GPR22) is an orphan class A rhodopsin-like GPCR primarily expressed in the heart and brain, as well as in chondrocytes under some pathological conditions. It possesses seven transmembrane helices and couples to inhibitory G proteins (Gi/Go) in transfected systems, resulting in adenylyl cyclase inhibition. GPR22 is implicated in the regulation of cardiac stress responses, cilia structure and function, and left-right axis development. It is part of a genetic locus associated with osteoarthritis susceptibility, although its direct role in disease remains debated. No endogenous or synthetic ligands for GPR22 have been identified, limiting therapeutic exploration. The receptor’s physiological and pathological significance warrants ongoing research, particularly regarding cardiac protection and ciliogenesis[2][3][4].

Other names
GPR22G protein-coupled receptor 22probable G protein-coupled receptor 22
02

Mechanism of action

For GPR22, transfected cell studies indicate constitutive coupling to Gi/Go proteins, leading to inhibition of adenylyl cyclase and decreased cAMP levels[2][4]. (No approved drugs, so therapeutic mechanism is hypothetical.)

03

Biological functions

Signal transduction via G proteins[1][2][4]Regulation of cilia length and structure[4]Protection against cardiac stress/hemodynamic overload[2][4]Implicated in left-right axis formation during development[4]
04

Disease associations

Cardiovascular disease (protection against cardiac stress)[2]Possible involvement in osteoarthritis (OA susceptibility locus)[4]Potential relevance in developmental biology (ciliogenesis disorders and LR patterning defects)[4]
05

Safety considerations

Notable challenges include lack of endogenous ligand, limited functional characterization, and uncertain physiological/pathological roles[2][4].As an orphan receptor, off-target or unexpected effects may arise if modulated therapeutically.
06

Biomarkers

None established. GPR22 expression in heart, brain, articular cartilage (in certain models) may have future biomarker utility[2][4]. No validated clinical biomarkers for patient selection or monitoring.

Beyond the preview

Go deeper on G protein-coupled receptor 22 (GPR22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G protein-coupled receptor 22 (GPR22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call